Original article
English
Abulayha AM, Tabal SA, Shawesh EI, Elbasir MA, Elbanani AS, Lamami YM, Bredan A.
Cell Biology Research Group, Biotechnology Research Center, Twisha, Tripoli, Libya. abdulmunem09@hotmail.com
Leuk Res. 2010 Mar;34(3):307-11.
Abstract
The monoclonal antibody Rituximab is useful for treatment of patients with B-cell non-Hodgkin’s lymphoma. We phenotypically analyzed reconstitution of peripheral B cells in a male patient with follicular lymphoma following their depletion with Rituximab. CD19+ and CD20+ B cell counts in peripheral blood decreased rapidly following Rituximab treatment. Six months after the end of treatment, a few CD19+ B cells were detected in peripheral blood. These cells had a naive B cell phenotype (IgD+, CD27-) and they expressed high levels of CD38 and CD24, which show that the B cell pool was repopulated mainly with immature, naive B cells.
Keywords: Rituximab, B cells, CD20, CD19, Recovery
Link/DOI: http://www.lrjournal.com/article/S0145-2126%2809%2900282-3/fulltext